Bonsignore Maria R, Profita Mirella, Gagliardo Rosalia, Riccobono Loredana, Chiappara Giuseppina, Pace Elisabetta, Gjomarkaj Mark
Biomedical Dept of Internal and Specialistic Medicine (DiBiMIS), Pneumology, University of Palermo, Palermo, Italy Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy
Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy.
Eur Respir Rev. 2015 Mar;24(135):30-9. doi: 10.1183/09059180.10011114.
Maurizio Vignola was a superb and innovative researcher, who wrote seminal papers on the biology of airway epithelium in asthma. Inflammation and remodelling were the main topics of his research, mostly conducted in biopsy specimens from patients with asthma of variable severity, encompassing the entire spectrum of the disease from mild to severe asthma. His observations contributed to define the biology of asthma as we know it today, and opened the way to the personalised treatment of asthma. His group has successfully continued to investigate the biology and clinical aspects of bronchial asthma, with major interest in the clinical use of biomarkers to monitor disease activity, and in the development of new therapeutic perspectives. This review summarises the latest work on these topics proudly conducted by Maurizio's closest collaborators. The results indicate significant progress in our understanding of asthma in the last 10 years, in particular increased knowledge of the complex interaction between inflammatory and remodelling pathways, improved recognition of biological and clinical asthma phenotypes, and development of new treatment strategies, especially for patients with severe corticosteroid-resistant asthma.
毛里齐奥·维尼奥拉是一位卓越且富有创新精神的研究者，他撰写了关于哮喘气道上皮生物学的开创性论文。炎症和重塑是他研究的主要主题，大多在不同严重程度哮喘患者的活检标本中进行，涵盖了从轻度到重度哮喘的整个疾病谱。他的观察结果有助于界定我们如今所知的哮喘生物学，并为哮喘的个性化治疗开辟了道路。他的团队成功地持续研究支气管哮喘的生物学和临床方面，主要关注生物标志物在监测疾病活动中的临床应用，以及新治疗前景的开发。这篇综述总结了毛里齐奥最亲密的合作者们自豪地在这些主题上开展的最新工作。结果表明，在过去10年里，我们对哮喘的理解取得了重大进展，尤其是对炎症和重塑途径之间复杂相互作用的认识有所增加，对生物和临床哮喘表型的识别得到改善，以及新治疗策略的开发，特别是针对严重糖皮质激素抵抗性哮喘患者。
